Core Insights - Quoin Pharmaceuticals Ltd. has successfully achieved target loading concentrations of 4% and 5% for its topical rapamycin delivery technologies, which are set to advance into clinical trial and stability batch manufacturing by Q4 2025, with clinical testing expected to begin in the first half of 2026 [1][2] Company Overview - Quoin Pharmaceuticals Ltd. is a late clinical stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases, with a pipeline that includes products targeting conditions such as Netherton Syndrome, Peeling Skin Syndrome, and various vascular malformations [3] Product Development - The company has developed two proprietary delivery systems for rapamycin, achieving a 4% w/w loading in a topical formulation and a 5% w/w loading in a dermal patch system, which may offer competitive advantages over existing formulations [1][2] - Initial clinical indications for testing include Microcystic Lymphatic Malformations and Venous Malformations, both of which currently lack FDA-approved treatments [1][2] Clinical and Financial Milestones - Quoin plans to initiate formal clinical development for its identified indications and has recently completed a capital raise to fund ongoing studies, including pivotal studies for Netherton Syndrome [2]